Aducanumab & FDA transparency in the news. @US_FDA appears on the cusp of approval, & Biogen's market cap surged >$10B, but does the drug actually work? At least one expert FDA statistician isn't convinced. If the drug is approved, will FDA keep that expert's analysis secret? 1/ https://twitter.com/jsross119/status/1324029550431473664
In years past, we could have felt confident that FDA would disclose Massie's (& all experts') full analyses upon approval. For years, FDA published the analyses of each expert reviewer & review team, a vital source of data, & insights into concerns & dissent within FDA 3/
In fact, federal law requires FDA to publish its experts' individual "reviews." Statute even specifies, "[a] scientific review of an application is considered the work of the reviewer and shall not be altered by management or the reviewer once final." 4/ https://www.law.cornell.edu/uscode/text/21/355
Yet in recent months, FDA announced it will cease publishing its experts' individual reviews as a matter of course. It will shift to an "integrated review" format that consolidates all reviewers analyses into a single document approved by FDA management 5/ https://www.fda.gov/drugs/regulatory-science-research-and-education/modernizing-fdas-new-drugs-regulatory-program
Oops, the preceding tweet is 6/6, not 7/7. Will I ever successfully proofread a tweet? It is as if I have face blindness, but for recognizing typos in tweets. I swear, prospective co-authors and collaborators, I'm not like this in other formats.
You can follow @cmorten2.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.